Top 10 IncobotulinumtoxinA (Xeomin) Biosimilar Manufacturers in United Kingdom
The market for biosimilars, particularly those related to incobotulinumtoxinA (Xeomin), is witnessing significant growth in the United Kingdom. With a projected market size of £300 million by 2025, the demand for effective and cost-efficient alternatives to branded botulinum toxin products is on the rise. As of 2023, the UK biosimilar market represented approximately 30% of the overall botulinum toxin market, underscoring the increasing acceptance and adoption of biosimilars among healthcare professionals and patients alike.
1. Mylan N.V.
Mylan, now part of Viatris following a merger, is a key player in the biosimilar market in the UK. Mylan’s biosimilar portfolio includes a product similar to Xeomin, contributing significantly to their market share. The company reported revenues of approximately $11.5 billion in 2022, with a growing segment in biosimilars.
2. Sandoz (Novartis)
Sandoz, a division of Novartis, is a leader in the biosimilar sector in the UK. With over 50 biosimilars in its portfolio, Sandoz is recognized for its robust quality assurance practices. The company has captured around 25% of the UK biosimilar market, generating approximately £75 million in revenue from its botulinum toxin products.
3. Allergan (AbbVie)
Allergan, known for its branded Botox product, is also venturing into the biosimilar domain. Though primarily focused on the branded market, Allergan’s research and development efforts are expected to launch biosimilars in the near future. They currently hold a market share of about 15% in the UK’s botulinum toxin market.
4. Ipsen S.A.
Ipsen is a prominent biopharmaceutical group that has developed a biosimilar product similar to Xeomin. With a focus on therapeutic areas including oncology and neuroscience, Ipsen has captured approximately 10% of the UK market. Their revenue from botulinum toxin products has reached around £50 million in the past year.
5. Galderma
Galderma specializes in dermatological products and has made inroads into the biosimilar market. Their botulinum toxin product is gaining traction, contributing to their overall revenue of approximately £100 million in 2022. Galderma holds about 8% of the UK market share for botulinum toxins.
6. Hugel, Inc.
South Korea’s Hugel has expanded its reach into the UK market, offering a biosimilar comparable to Xeomin. The company has reported a 15% increase in sales year-on-year, amounting to £10 million in the UK. Their strategic marketing efforts are aimed at increasing brand recognition.
7. Revance Therapeutics, Inc.
Revance, known for its innovative neuromodulator products, is working on a biosimilar to Xeomin. Although still in the early stages, their unique delivery system is expected to enhance market penetration. Revance has garnered significant interest, with projected revenues of £5 million in the UK by 2025.
8. EirGenix, Inc.
EirGenix offers a biosimilar that competes with established products like Xeomin. The company, based in Taiwan, has begun distribution in the UK, with initial sales figures around £3 million. Their focus on quality and affordability is driving early adoption.
9. Coherus BioSciences, Inc.
Coherus has recently entered the UK market with a biosimilar targeting the botulinum toxin segment. Their innovative approach in formulation is aimed at enhancing patient outcomes. Current estimates suggest revenues of around £1.5 million, with expectations for growth.
10. Amgen Inc.
Amgen, primarily known for its biologic products, has expressed interest in the botulinum toxin market. Though not yet launched in the UK, their biosimilar product is anticipated to capture a significant market share once available, with projections indicating potential revenues of £20 million by 2026.
Insights
The incobotulinumtoxinA (Xeomin) biosimilar market in the UK is expanding rapidly, driven by increasing healthcare costs and a demand for affordable treatment options. The UK biosimilar market is expected to grow at a compound annual growth rate (CAGR) of 15% from 2023 to 2025. As more manufacturers enter the fray, competition will likely drive innovation and cost reductions, benefiting patients and healthcare providers alike. The increasing acceptance of biosimilars among clinicians and patients indicates a promising future for these competitors in the UK market.
Related Analysis: View Previous Industry Report
